SNCA and melanoma: While studies in melanoma and pancreatic cancer have revealed marked differences in gut microbiota composition and diversity between responders and non-responders to anti-PD-1 therapy, such data are notably absent in glioblastoma due to its poor response to immunotherapy [64,65].